About Achillion
Achillion is a Healthcare company based in New Haven (United States) founded in 1998, and was acquired by Alexion in October 2019. It operates as a treatments for Hepatitis C and complement-mediated diseases are developed. Achillion has raised $41 million across 1 funding round from investors including Alexion, Schroders and GE Capital. Its chief executive is Milind Deshpande. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Achillion Pharmaceuticals was founded in 1998 and is based in New Haven, United States, within the biotechnology sector. Focus is placed on developing oral drugs for chronic Hepatitis C, with the lead candidate advancing through phase II trials in partnership with Janssen. An additional Factor D inhibitor is under early-stage evaluation for paroxysmal nocturnal hemoglobinuria, dry age-related macular degeneration, and chronic obstructive pulmonary disease.
- Headquarters New Haven, United States
- Stage Acquired
- SectorsHealthcare
- Website achillion.com
- Social LinkedIn X YouTube
- Acquired by Alexion (Oct 2019)
Apps and channels of Achillion
its YouTube channel Alexion Pharmaceuticals US has 233 subscribers and 30 videos.
Videos from Achillion
The most watched videos on Achillion's YouTube channel, Alexion Pharmaceuticals US (233 subscribers). Click a video to play it here.
More on Alexion Pharmaceuticals US.
Funding Insights of Achillion
Achillion has successfully raised a total of $41M through 1 strategic funding round. The most recent funding activity was a Series C round of $41 million completed in January 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41M
- Total Rounds 1
- Last Round Series C — $41M
- First Round $41M
(Jan 2002)
- Investors Count 8
All 1 funding rounds of Achillion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2002 | $41M | Series C | – | Bear Stearns Companies |
9 investors in total: 9 institutional.
Investors in Achillion
Achillion has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alexion, Schroders and GE Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | – | adventinternational.com | Sao Paulo, Brazil | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
Limited information is provided about KBL Healthcare Ventures. | – | kblhealthcare.com | - | |
Growth stage VC fund investing in the US, Europe and Canada | – | oakwoodmedical.com | St. Louis, United States | |
Investment and wealth planning services are provided to clients. | 1995 | bearstearns.com | New York, United States | |
Commercial aircraft and equipment leasing and lending services are provided. | 1932 | gecapital.com | United States | |
Investment management and wealth management services are provided to clients. | 1804 | schroders.com | London, United Kingdom | |
Therapies for rare and devastating diseases are developed by Alexion. | 1992 | alexion.com | Zurich, Switzerland |
Investor details for Achillion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Achillion
12 people are tracked at Achillion (7 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Milind Deshpande | CEO | Leadership |
Susanne Heinzinger | Senior Vice President, Commercial Strategy, Patient Advocacy and Communications | Leadership |
Anthony S. Gibney | Executive Vice President, Chief Business Officer | Leadership |
Heather Robison | Sr Director, Biometrics And Data Management | Leadership |
Paul Firuta | Executive Vice President, Chief Operating Officer | Leadership |
David Apelian | Chief Medical Officer | Leadership |
Laura Barrow | Vice President & Head Clinical Operations And Project Management | Leadership |
Brit Shell | Senior Medical/regulatory Writer | Team |
Paula Dinello | Electronic Publisher/submission Specialist | Team |
Michael Elliot | Senior Research Scientist | Team |
Crit Marlor | Principal Scientist | Team |
Jose Rivera | Principal Scientist | Team |
Complete people profiles for Achillion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Achillion
4 dated milestones of Achillion across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Achillion is founded.
- Funding First funding round of $41.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Alexion.
Competitors of Achillion
Achillion has 9 listed competitors in our database, 9 of them funded. They include Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis | |
| aligos.com | 2018 | San Francisco, United States | $225M | 70 | Developer of therapies to treat hepatologic diseases and viral infections | |
| ausperbio.com | 2019 | San Mateo, United States | $223M | – | Therapies for chronic hepatitis B and infectious diseases are developed. | |
| ascentagepharma.com | 2009 | Hong Kong, China | $237.5M | – | Small molecule drugs for cancer treatment are developed. | |
| bluejaytx.com | 2019 | San Francisco, United States | $243M | 3 | Therapeutics for infectious diseases treatment are developed. | |
| presidiopharma.com | 2006 | San Francisco, United States | $91.93M | – | Small-molecule antiviral therapeutics for hepatitis C are developed. | |
| finchtherapeutics.com | 2004 | Somerville, United States | $184M | – | Microbiome-based therapies are developed via human-first discovery platform. | |
| xtyw.com.cn | 2000 | Xi An, China | $14.61M | – | Drugs for treating infectious and liver diseases are developed. | |
| carogencorp.com | 2012 | Hamden, United States | $2.23M | – | Recombinant protein nanoparticle vaccines for hepatitis B are developed. |
Detailed competitors of Achillion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Achillion
Websites that share an audience with Achillion (achillion.com).
Websites whose visitors overlap most with Achillion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rib-x.com | rib-x.com | 100% | – | – | – |
| shire.com | 83% | 1.4K | #14,679,892 | View details | |
merrimackpharma.com | merrimackpharma.com | 79% | – | – | – |
| celgene.com | 78% | – | – | View details | |
| advaxis.com | 78% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Achillion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Achillion (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Achillion
Complete news archive for Achillion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Achillion
Achillion was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Achillion is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Milind Deshpande is the current CEO of Achillion.
Achillion is a funded company, having raised a total of $41M across 1 funding round to date. The company's 1st funding round was a Series C of $41M, raised on Jan 2002.
Achillion Pharmaceuticals was founded in 1998 and is based in New Haven, United States, within the biotechnology sector. Focus is placed on developing oral drugs for chronic Hepatitis C, with the lead candidate advancing through phase II trials in partnership with Janssen. An additional Factor D inhibitor is under early-stage evaluation for paroxysmal nocturnal hemoglobinuria, dry age-related macular degeneration, and chronic obstructive pulmonary disease.
Achillion's top competitors include Eiger BioPharmaceuticals, AusperBio and Finch Therapeutics.
Achillion has 9 investors. Key investors include Alexion, Schroders, GE Capital, Atlas Venture, and Bear Stearns Companies.
Yes. Achillion was acquired by Alexion in October 2019.